Home Respiratory Distress Syndrome About Surfactants About Infasurf Frequently Asked Questions Request Additional Information

Welcome to Infasurf.com

Infasurf is indicated for the PREVENTION of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the TREATMENT "rescue" of newborn infants who develop RDS. Infasurf decreases the incidence of RDS when used as prevention. When used either to prevent or treat RDS, Infasurf lowers the incidence of lung air leaks (pneumothorax, pneumomediastinum, and pulmonary interstitial emphysema) and reduces the mortality associated with RDS.

Prescribing Information
Request Additional Information

CORPORATE OFFICES
ONY, Inc.
1576 Sweet Home Rd, Amherst, NY 14228
Tel: (716) 636-9096;
Toll-free (877) 274-4669
E-mail: info@onyinc.com

ORDERING OPTIONS
Contact your regular wholesaler, or
Call McKesson Specialty Care Solutions:
(877) 362-7278
Ordering questions/difficulties: Call Toll-free (877) 274-4669
E-mail: order@onyinc.com

INFASURF PRODUCT COMPLAINTS
Toll-free: (877) 663-4179
E-mail: product@onyinc.com

INFASURF DRUG SAFETY ISSUES
Toll-free: (877) 663-4179
E-mail: safety@onyinc.com

Administration of exogenous surfactants, including INFASURF, often rapidly improve oxygenation and lung compliance. Following INFASURF administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with INFASURF, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.
© 2010 ONY, Inc.
Legal Statement | Privacy Policy | Contact Us | Site Map